Erastin: Benchmark Ferroptosis Inducer for Cancer Biology Research

Executive Summary: Erastin (SKU B1524) is a selective small molecule that induces ferroptosis, an iron-dependent, caspase-independent cell death pathway, primarily in tumor cells with RAS or BRAF mutations (APExBIO). Mechanistically, it targets the cystine/glutamate antiporter system Xc⁻ and modulates VDAC, leading to lethal reactive oxygen species (ROS) accumulation. Erastin is insoluble in water but dissolves in DMSO at ≥10.92 mg/mL with gentle warming and is unstable for long-term solution storage. Research demonstrates its utility in modeling ferroptosis and exploring redox vulnerabilities in cancer, notably under 10 μM, 24-hour conditions in engineered or HT-1080 tumor cells (Gupta et al., 2025). This article details Erastin's mechanistic basis, experimental benchmarks, and integration in cancer biology workflows.

Biological Rationale

Ferroptosis is a regulated form of cell death characterized by iron dependency and lipid peroxidation distinct from apoptosis or necrosis (Gupta et al., 2025). Tumor cells with mutations in the RAS family (HRAS, KRAS) or BRAF genes show increased sensitivity to ferroptosis due to altered redox homeostasis. These mutations often drive resistance to apoptosis and standard chemotherapeutics, necessitating alternative cell death modalities. The targeting of system Xc⁻, critical for importing cystine and maintaining glutathione (GSH) levels, exposes a vulnerability in these cancer cells. By inhibiting this transporter, Erastin deprives the cell of cystine, reducing GSH, and tipping the redox balance toward lethal oxidative stress. This strategy is foundational in cancer biology, offering a path to circumvent traditional drug resistance (related article; this article extends mechanistic depth and current benchmarks).

Mechanism of Action of Erastin

Erastin exerts its effect primarily through two molecular targets:

• System Xc⁻ Inhibition: Erastin inhibits the cystine/glutamate antiporter (SLC7A11/xCT), reducing cystine import and depleting intracellular GSH (APExBIO).
• VDAC Modulation: It binds to and alters the voltage-dependent anion channel (VDAC) on the mitochondrial membrane, increasing mitochondrial permeability and amplifying ROS generation (Gupta et al., 2025).

The combined effect is a rapid accumulation of ROS and lipid peroxides, culminating in ferroptotic cell death without classical caspase activation. This distinguishes Erastin-induced cell death from apoptosis and necroptosis, as confirmed by the absence of PARP cleavage and caspase-3 activation in benchmark studies.

Evidence & Benchmarks

• Erastin at 10 μM for 24 hours induces >80% cell death in HT-1080 fibrosarcoma cells via ferroptosis, not apoptosis (Gupta et al., 2025, https://doi.org/10.1186/s12951-025-03657-8).
• System Xc⁻ inhibition reduces intracellular cystine and GSH by >60% within 6 hours of Erastin exposure (APExBIO, https://www.apexbt.com/erastin.html).
• Erastin triggers significant ROS accumulation (3–5 fold increase) and mitochondrial membrane potential (ΔΨm) loss in RAS/BRAF-mutant tumor cells compared to wild-type controls (Gupta et al., 2025, https://doi.org/10.1186/s12951-025-03657-8).
• Cell death is iron-dependent: chelators (e.g., deferoxamine) abrogate Erastin-induced cytotoxicity (Gupta et al., 2025, https://doi.org/10.1186/s12951-025-03657-8).
• Erastin does not induce cell death in non-tumorigenic or wild-type RAS/BRAF cell lines under identical conditions (APExBIO, https://www.apexbt.com/erastin.html).

This article provides updated, verified benchmarks compared to previous strategic guidance, clarifying iron dependency and cell-type specificity.

Applications, Limits & Misconceptions

Erastin is essential for:

• Ferroptosis Research: Dissecting iron-dependent, non-apoptotic cell death mechanisms.
• Cancer Biology: Studying redox vulnerabilities in RAS- and BRAF-mutant tumors.
• Oxidative Stress Assays: Validating ROS and lipid peroxidation as cell death triggers.
• Drug Discovery: Screening for ferroptosis modulators in oncology.

Limits include:

• Selective action: Ineffective in non-mutant, non-transformed cells at standard doses.
• Solution stability: Erastin solutions are not stable long-term; fresh preparation is required.
• Solubility: Insoluble in water or ethanol; requires DMSO for dissolution at ≥10.92 mg/mL.
• Not a direct therapeutic agent: Current use is preclinical research only.

Common Pitfalls or Misconceptions

• Misapplying Erastin in apoptosis studies—ferroptosis is caspase-independent.
• Assuming efficacy in all tumor types—sensitivity is highest in RAS/BRAF-mutant lines.
• Using old solutions—degraded Erastin leads to inconsistent results.
• Solubilizing in aqueous buffers—Erastin precipitates and loses activity.
• Neglecting iron chelators—iron chelation will block Erastin's effects and confound interpretation.

This article clarifies these points beyond prior summaries such as this mechanistic overview.

Workflow Integration & Parameters

For experimental use, dissolve Erastin in DMSO at concentrations ≥10.92 mg/mL with gentle warming (APExBIO). Store the powder at -20°C in desiccated conditions. Prepare working solutions freshly before each experiment; do not store reconstituted solutions for >24 hours. Typical dosing is 10 μM for 24 hours in engineered human tumor cells or the HT-1080 line. Monitor ferroptosis via ROS, lipid peroxidation, and cell viability assays. Iron chelators can serve as specificity controls. For protocol scenarios and troubleshooting, see practical guidance in this scenario-based solutions article, which this article extends by providing updated experimental benchmarks and stability notes.

Conclusion & Outlook

Erastin (SKU B1524) from APExBIO is a gold-standard reagent for ferroptosis research, offering selective, reliable induction of iron-dependent, non-apoptotic cell death in cancer models. Its action on system Xc⁻ and VDAC underpins translational studies in redox biology and oncology. While not a clinical therapy, it is indispensable for dissecting cell death pathways and may guide future therapeutic innovations targeting ferroptosis in resistant cancers. For product details and ordering, visit the Erastin product page.